Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Retrieved on: 2025-05-14 11:45:26

Tags for this article:

Click the tags to see associated articles and topics

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments. View article details on hiswai:

Excerpt

Goldman Sachs owns a 3.3% stake in Septerna, while healthcare-focused venture capital firm Third Rock Ventures holds 23.7%, according to LSEG data.

Article found on: finance.yahoo.com